{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:01:10Z","timestamp":1751774470725,"version":"3.41.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.2169\/internalmedicine.4503-24","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T22:13:57Z","timestamp":1735164837000},"page":"2073-2079","source":"Crossref","is-referenced-by-count":0,"title":["Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab"],"prefix":"10.2169","volume":"64","author":[{"given":"Takuma","family":"Tsuzuki Wada","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Saitama Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiji","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Saitama Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015.","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477, 2005.","DOI":"10.1084\/jem.20050304"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-830, 1956.","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fujimoto S, Koga T, Kawakami A, et al. Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan. Mod Rheumatol 28: 161-167, 2018.","DOI":"10.1080\/14397595.2017.1366093"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706, 2011.","DOI":"10.1073\/pnas.1017385108"},{"key":"6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","volume":"74","author":"K Yoshizaki","year":"1989","unstructured":"6. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman&apos;s disease. Blood 74: 1360-1367, 1989.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V78.11.2923.2923","volume":"78","author":"MB Leger-Ravet","year":"1991","unstructured":"7. Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman&apos;s disease. Blood 78: 2923-2930, 1991.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82: 1302-1306, 2014.","DOI":"10.1212\/WNL.0000000000000317"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhang C, Zhang M, Qiu W, et al.; the TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19: 391-401, 2020.","DOI":"10.1016\/S1474-4422(20)30070-3"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627-2632, 2005.","DOI":"10.1182\/blood-2004-12-4602"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Higuchi T, Nakanishi T, Takada K, et al. A case of multicentric Castleman&apos;s disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. J Korean Med Sci 25: 1364-1367, 2010.","DOI":"10.3346\/jkms.2010.25.9.1364"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takai Y, Kuroda H, Misu T, et al. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 49: 102750, 2021.","DOI":"10.1016\/j.msard.2021.102750"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381: 2114-2124, 2019.","DOI":"10.1056\/NEJMoa1901747"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19: 402-412, 2020.","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Elhassanien AF, Aziz HA. Acute demyelinating encephalomyelitis: clinical characteristics and outcome. J Pediatr Neurosci 8: 26-30, 2013.","DOI":"10.4103\/1817-1745.111418"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pagni F, Bosisio FM, Sala E, et al. The plasmablasts in Castleman disease. Am J Clin Pathol 139: 555-559, 2013.","DOI":"10.1309\/AJCP5MCR0ETAAKZK"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nakaya Y, Ishii N, Kasamatsu Y, et al. Human herpesvirus 8-positive multicentric Castleman disease with germinotropic plasmablastic aggregates: overlapping spectrum of human herpesvirus 8-associated lymphoproliferative disorder. Pathol Int 70: 574-580, 2020.","DOI":"10.1111\/pin.12951"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wandinger KP, Stangel M, Witte T, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sj\u00f6gren&apos;s syndrome. Arthritis Rheum 62: 1198-1200, 2010.","DOI":"10.1002\/art.27337"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Murakami M, Johkoh T, Hayashi S, et al. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Mod Rheumatol 30: 843-851, 2020.","DOI":"10.1080\/14397595.2019.1704983"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim U, Hwang JM. Optic neuropathy associated with Castleman disease. Korean J Ophthalmol 24: 256-259, 2010.","DOI":"10.3341\/kjo.2010.24.4.256"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Epps SJ, Lowry L, Guly CM. Bilateral optic neuropathy associated with Castleman disease. Br J Haematol 167: 439, 2014.","DOI":"10.1111\/bjh.13057"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/13\/64_4503-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:46:16Z","timestamp":1751687176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/13\/64_4503-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4503-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"4503-24"}}